Outcomes and endpoints of postoperative recurrence in Crohn's Disease: systematic review and consensus conference.

Biotherapy Clinical trials IBD Surgery Treatment

Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
19 Dec 2023
Historique:
received: 18 09 2023
medline: 19 12 2023
pubmed: 19 12 2023
entrez: 19 12 2023
Statut: aheadofprint

Résumé

Outcomes after ileocolonic resection in Crohn's Disease (CD) are heterogeneous and a clear definition of postoperative recurrence remains to be determined. Our Endpoints Working Group of the International Organization for the study of Inflammatory Bowel Disease (IOIBD) aimed to standardize postoperative outcomes, to discuss which endpoints should be used for postoperative clinical trials and to define those which could be used in trials or registries. Based on a systematic review of the literature, recommendations and statements were drafted and sent to all IOIBD members for a first round of voting. Recommendations and statements were revised based on the voters' comments during a consensus hybrid conference open to all IOIBD members. If no agreement was reached after 2 rounds of voting, the statement was excluded. In the systematic review, 3,071 manuscripts were screened, of which 434 were included. Sixteen recommendations were identified, of which 11 were endorsed. Recommendations and statements include that endoscopy remains the gold standard and should be used as a short-term primary endpoint in both observational cohorts and randomized controlled trials. Clinical symptoms classically used in clinical trials for luminal CD are not reliable in this specific situation. For that reason, longer term endpoints should be based on the evidence of macroscopic inflammation assessed by imaging techniques, endoscopy or reflected by the presence of complications. Agencies recommend the use of clinical evaluations, as in the case of luminal CD, and do not recognize primary endpoints based solely on endoscopy. This consensus has led to agreement on the need to define postoperative endoscopy- and/or imaging-based endpoints.

Sections du résumé

BACKGROUND BACKGROUND
Outcomes after ileocolonic resection in Crohn's Disease (CD) are heterogeneous and a clear definition of postoperative recurrence remains to be determined. Our Endpoints Working Group of the International Organization for the study of Inflammatory Bowel Disease (IOIBD) aimed to standardize postoperative outcomes, to discuss which endpoints should be used for postoperative clinical trials and to define those which could be used in trials or registries.
METHODS METHODS
Based on a systematic review of the literature, recommendations and statements were drafted and sent to all IOIBD members for a first round of voting. Recommendations and statements were revised based on the voters' comments during a consensus hybrid conference open to all IOIBD members. If no agreement was reached after 2 rounds of voting, the statement was excluded.
RESULTS RESULTS
In the systematic review, 3,071 manuscripts were screened, of which 434 were included. Sixteen recommendations were identified, of which 11 were endorsed. Recommendations and statements include that endoscopy remains the gold standard and should be used as a short-term primary endpoint in both observational cohorts and randomized controlled trials. Clinical symptoms classically used in clinical trials for luminal CD are not reliable in this specific situation. For that reason, longer term endpoints should be based on the evidence of macroscopic inflammation assessed by imaging techniques, endoscopy or reflected by the presence of complications.
CONCLUSIONS CONCLUSIONS
Agencies recommend the use of clinical evaluations, as in the case of luminal CD, and do not recognize primary endpoints based solely on endoscopy. This consensus has led to agreement on the need to define postoperative endoscopy- and/or imaging-based endpoints.

Identifiants

pubmed: 38112601
pii: 7478410
doi: 10.1093/ecco-jcc/jjad205
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Nassim Hammoudi (N)

Department of Gastroenterology, Hôpital Saint-Louis, AP-HP, INSERM U1160, Université Paris Cité, Paris, France.

David Sachar (D)

Icahn School of Medicine at Mount Sinai, New York, USA.

Geert D'Haens (G)

Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

Walter Reinisch (W)

Department Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.

Paulo Gustavo Kotze (PG)

Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil.

Severine Vermeire (S)

Department of Gastroenterology & Hepatology, University Hospital Leuven, Leuven, Belgium.

Jürgen Schölmerich (J)

Prof. Emeritus University of Frankfurt, Germany.

Michael A Kamm (MA)

Department of Gastroenterology, St Vincent's Hospital, and Department of Medicine University of Melbourne, Melbourne, Australia.

Anne Griffiths (A)

IBD Centre, SickKids Hospital, University of Toronto, Toronto, Canada.

Julian Panes (J)

Formerly Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.

Subrata Ghosh (S)

APC Microbiome Ireland, College of Medicine and Health, University College Cork, Ireland.

Corey A Siegel (CA)

IBD Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03755, USA.

Willem Bemelman (W)

Department of Surgery, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.

Colm O'Morain (C)

Faculty of Health Sciences, Trinity College Dublin, Ireland.

Flavio Steinwurz (F)

Department of Gastroenterology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

Phillip Fleshner (P)

Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, USA.

Gerassimos J Mantzaris (GJ)

Consultant Gastroenterologist; White Cross, The Athens Clinic and HYGEIA Hospital, Athens, Greece.

Bruce Sands (B)

Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Maria T Abreu (MT)

Department of Medicine, Division of Gastroenterology, Crohn's and Colitis Center, Leonard M. Miller School of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.

Iris Dotan (I)

Division of Gastroenterology, Rabin Medica Center, Petah-Tikva, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dan Turner (D)

The Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, The Faculty of Medicine the Hebrew University of Jerusalem, Israel.

Axel Dignass (A)

Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt Am Main, Germany.

Matthieu Allez (M)

Department of Gastroenterology, Hôpital Saint-Louis, AP-HP, INSERM U1160, Université Paris Cité, Paris, France.

Classifications MeSH